Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line

NCT03292822 | Completed Phase 1 DMC

• 1 other identifier: CEBD-CU-2017-09-26
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

Oral squamous cell carcinoma (OSCC) are considered as a one of the most malignant cancers. It has prognosis due to its distant metastasis and obvious destruction which lead to low survival rate. The conventional treatment modalities such as surgery, radiotherapy and chemotherapy are only the suitable strategies until now. Investigators cannot ignore the serious side effects of chemotherapy such as gastrointestinal upset, bone marrow suppression which cannot be overcome. For all these complications, there is a great need and demand to discover a new agents and strategies for treating OSCC. Licorice extract, especially Licochalcone A, is one of many natural extracts that have used as a traditional in treatment of inflammation, microbial infections. Regarding antitumor effect, Licochalcone A reveals interesting results in programmed cell death and apoptosis in cancer cells such as prostate, bladder, colon and gastric cancer.

Conditions

Squamous Cell Carcinoma

Outcome Measures

Primary Outcomes (1)

• Apoptosis

  programmed cell death

  3 days

Study Arms (2)

Licochalcone A

EXPERIMENTAL

Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties.

Dietary Supplement: Licochalcone A

Paclitaxel

ACTIVE COMPARATOR

chemotherapeutic drug

Drug: Paclitaxel

Interventions

Licochalcone A DIETARY_SUPPLEMENT

Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties in vitro.

Licochalcone A

Paclitaxel DRUG

chemotherapeutic drug

Also known as: taxol

Paclitaxel

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• All head and neck squamous cell carcinoma cell lines
• Licochalcone extracts
• Taxols group of chemotherapy

You may not qualify if:

• Animal experimental studies
• Any cancer cell line other than squamous cell carcinoma cell lines.
• Any chemotherapeutics other than Taxols group.

Sponsors & Collaborators

• Cairo University: lead

Study Sites (1)

Cairo University

Cairo, Egypt

Location

Related Publications (1)

• Park MR, Kim SG, Cho IA, Oh D, Kang KR, Lee SY, Moon SM, Cho SS, Yoon G, Kim CS, Oh JS, You JS, Kim DK, Seo YS, Im HJ, Kim JS. Licochalcone-A induces intrinsic and extrinsic apoptosis via ERK1/2 and p38 phosphorylation-mediated TRAIL expression in head and neck squamous carcinoma FaDu cells. Food Chem Toxicol. 2015 Mar;77:34-43. doi: 10.1016/j.fct.2014.12.013. Epub 2015 Jan 5.

  PMID: 25572524 BACKGROUND

MeSH Terms

Conditions

Carcinoma, Squamous Cell

Interventions

licochalcone A; Paclitaxel

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Squamous Cell

Intervention Hierarchy (Ancestors)

Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes

Study Officials

• Ahmed H El-Khadem, Phd

  Cairo University

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: teaching assistant

Study Record Dates

• First Submitted: September 12, 2017
• First Posted: September 26, 2017
• Study Start: February 15, 2021
• Primary Completion: January 1, 2023
• Study Completion: December 1, 2023
• Last Updated: June 20, 2024

Record last verified: 2024-06

Locations

EG (1)